Shopping Cart
- Remove All
Your shopping cart is currently empty
PF-06840003 (EOS200271) is a specific and orally active IDO-1 inhibitor.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $32 | In Stock | |
| 5 mg | $50 | In Stock | |
| 10 mg | $85 | In Stock | |
| 25 mg | $117 | In Stock | |
| 50 mg | $137 | In Stock | |
| 100 mg | $216 | In Stock | |
| 200 mg | $322 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $55 | In Stock |
| Description | PF-06840003 (EOS200271) is a specific and orally active IDO-1 inhibitor. |
| Targets&IC50 | IDO1 (mouse):1.5 μM, IDO1 (human):0.41 μM, dIDO1:0.59 μM |
| In vitro | The s of PF-06840003 has inhibitory for hIDO-1 (IC50: 0.41 μM), mouse IDO-1 (IC50: 1.5 μM) and dog IDO-1 (IC50: 0.59 μM), respectively. It has very weak inhibitory against hTDO-2 (IC50: 140 μM). In cellular assays, PF-06840003 shows activity both in the LPS/INFγ-stimulated THP1 cells (IC50: 1.7 μM) and in the HeLa assay (IC50: 1.8 μM). PF-06840003 is a very weak inhibitory against CYPs (IC50>100 μM) except 2C19 (IC50: 78 μM). |
| In vivo | In mice, PF-06840003 reduces intratumoral kynurenine levels (>80%). In multiple preClinicalal syngeneic models in mice, It inhibits tumor growth by combinated with immune checkpoint inhibitors. PF-0684003 has favorable predicted human pharmacokinetic properties, including a predicted t1/2 of 16-19 hours. |
| Synonyms | PF 06840003, EOS200271 |
| Molecular Weight | 232.21 |
| Formula | C12H9FN2O2 |
| Cas No. | 198474-05-4 |
| Smiles | Fc1ccc2[nH]cc(C3CC(=O)NC3=O)c2c1 |
| Relative Density. | 1.464 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (258.39 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.